Big Pharma Teams Up with St. Louis Immunotherapy Startup & Why it Matters
Immunophotonics has announced a research collaboration with the innovation subsidiary of a major pharmaceutical company to study the effect of combining an immunotherapy drug with routine treatments for cancer in order to reduce the risk of recurrence. EQ speaks to the STL startup founder and explains 4 reasons why this is good news for St. Louis.
The post Big Pharma Teams Up with St. Louis Immunotherapy Startup & Why it Matters appeared first on EQ.